Shiraz University of Medical Sciences
Trends in Pharmaceutical Sciences
2423-3722
2423-5652
6
1
2020
03
01
A glance at Berberis integerimma pharmacological effects and its active constituents
1
10
EN
Mahmoudreza
Moein
0000-0002-3355-4654
Department of Pharmacognosy, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
mrmoein@sums.ac.ir
Zahra
Sabahi
0000-0002-6760-1009
Medicinal Plants Processing Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
sabahiz@sums.ac.ir
Hasti
Salim
Medicinal Plants Processing Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
salimhasti1993@gmail.com
10.30476/tips.2020.83414.1024
Berberis integerimma (family: Berberidaceae) is broadly used in the pharmacological studies as a rich source of bioactive compounds.<br /> Phytochemical investigations reveal that Berberis integerimma (B. integerimma) contains <br /> alkaloids derivates. <br /> Material and methods: this study introduced pharmacological effects of B. integerimma by reviewing the plant related study through available databases including Web of Science, Pub Med and Google Scholar. The present review attempts to give a short overview on the pharmacological studies and active compounds of B. integerimma with emphasis on some mechanisms of activities.<br /> Results: scientific evidence suggested the possible therapeutic properties of this plant on diseases such as diabetes, inflammation,free radicals associated diseases, seizure and cancer.<br /> Conclusion: <br /> In this review, we evaluated the most correlated original articles to determine the role of B. integerima on different medical conditions. This suggests a potential role of B. integrimma in the managing of disease; however more studies, especially pharmacokinetic and clinical trials, need to be considered to evaluate their efficiency or reveal its toxicity and side effects.
Berberis integerimma,alkaloid,berberine,phytochemical constituents
https://tips.sums.ac.ir/article_46354.html
https://tips.sums.ac.ir/article_46354_0fe5f099a9b87ad30a15f14ef1d2623d.pdf
Shiraz University of Medical Sciences
Trends in Pharmaceutical Sciences
2423-3722
2423-5652
6
1
2020
03
01
An in Silico Approach to Find the Molecular Targets and Potential Candidates for SARS-CoV-2
11
20
EN
Amir
Zarrinhaghighi
0000-0003-4012-5097
Department of Pharmaceutical Biotechnology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran
zarrinhaghighi.a@gmail.com
Ali
Dehshahri
0000-0003-4458-1292
Department of Pharmaceutical Biotechnology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
dehshahria@sums.ac.ir
10.30476/tips.2020.86025.1045
The rapid spread of SARS-CoV-2 has led researchers to seek novel drugs as well as re-purposing the existing drugs to prevent control or treat COVID-19. An interesting approach is to focus on the molecular pathways which could act as a drug target in this disease. Since the molecular pathways associated with SARS-CoV-2 are still unclear, the SARS-CoV infected patients and the convalescent individuals were selected as the model for SARS-CoV-2 infection and an in silico study was designed to identify the potential pathways which could act as the target for drug molecules. In the next step, the drugs with the ability to target these pathways were selected and introduced as potential compounds for further investigations to finding a drug for COVID-19. The results revealed that lycorine and GW-5074 are two small molecules with the ability to target the selected pathways. Interestingly, these compounds had shown antiviral activity against a broad range of viruses, including SARS-CoV. The results obtained in this in silico study could be considered as a primary study for further investigations.
SARS-CoV-2,COVID-19,molecular pathways,drug candidate
https://tips.sums.ac.ir/article_46485.html
https://tips.sums.ac.ir/article_46485_79a844e9130d99027547c280213c8f2f.pdf
Shiraz University of Medical Sciences
Trends in Pharmaceutical Sciences
2423-3722
2423-5652
6
1
2020
03
01
Formulation and Evaluation of Delayed Release Enteric Coated Tablets of Tenatoprazole, by Optimizing the Plymers
21
28
EN
Nikunja B
Pati
0000-0002-6544-1574
Dept. of Pharmaceutics, Faculty of Pharmaceutical Sciences, Jawaharlal Nehru Technological University (Pulla Reddy Institute of Pharmacy), Hyderabad, India.
nikunjapatipharmacy@gmail.com
Swapna
Velivela
Dept. of Pharmaceutics, Faculty of Pharmaceutical Sciences, Jawaharlal Nehru Technological University (Pulla Reddy Institute of Pharmacy), Hyderabad, India.
swapna.velivela@gmail.com
Vinyas
Mayasa
Dept. of Pharmaceutics, Faculty of Pharmaceutical Sciences, Jawaharlal Nehru Technological University (Pulla Reddy Institute of Pharmacy), Hyderabad, India.
vinyasmayasa7@gmail.com
Ravindra Babu
Baggi
Dept. of Pharmaceutics, Faculty of Pharmaceutical Sciences, Jawaharlal Nehru Technological University (Pulla Reddy Institute of Pharmacy), Hyderabad, India.
baggi.ravi39@gmail.com
10.30476/tips.2020.85126.1041
The present study was undertaken with an aim to formulate enteric coated tablets of Tenatoprazole (a novel proton pump inhibitor with an imidazopyridine ring) to improve bioavailability by avoiding degradation.<br /> Different core tablets were prepared using approved excipients by direct compression method and evaluated for different parameters like hardness, thickness, friability and disintegration time. Sub-coating was done for optimized formulation (F5) by using HPMC 5 cps with buildup of 3% w/w and finally enteric coating was done by using HPMCP, Eudragit L30 D55 and HPMC Acetate succinate (HPMCAS) with an average weight buildup of 5%, 8% and 10% w/w. all formulations were evaluated for different parameters like hardness, friability, thickness, disintegration time, drug content and dissolution studies and compared with marketed sample. Results indicated that, methacrylic acid polymers exhibited better dissolution rate than cellulose polymers. The optimized formulation was subjected to stability studies as per ICH guidelines for 3 months and was observed that no significant change was observed.
Sub-coating,enteric coating tablets,HPMCP,Eudragit L30 D55,HPMCAS,Stability studies
https://tips.sums.ac.ir/article_46498.html
https://tips.sums.ac.ir/article_46498_d03e62db1a4c4951dbe58e0eb224efcc.pdf
Shiraz University of Medical Sciences
Trends in Pharmaceutical Sciences
2423-3722
2423-5652
6
1
2020
03
01
Methylene Blue Treatment Enhances Mitochondrial Function and Locomotor Activity in a C57BL/6 Mouse Model of Multiple Sclerosis
29
42
EN
Mohammad Mehdi
Ommati
College of Life Sciences, Shanxi Agricultural University, Taigu, Shanxi 030801, Peoples&rsquo; Republic of China
mehdi_ommati@sums.ac.ir
Negar
Azarpira
0000-0002-5549-0057
Transplant Research Center, Shiraz University of Medical Sciences
negarazarpira@gmail.com
Forouzan
Khodaei
0000-0001-5950-4930
Pharmaceutical Sciences Research Center, Shiraz university of Medical Sciences, Shiraz, Iran
foroozan_009@yahoo.com
Hossein
Niknahad
0000-0001-6211-5936
Department of Pharmacology-Toxicology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
niknahadh@sums.ac.ir
Vahideh
Gozashtegan
Pharmaceutical Sciences Research Center, Shiraz university of Medical Sciences, Shiraz, Iran
vahide6490@yahoo.com
Reza
Heidari
0000-0002-7038-9838
Shiraz University of Medical Sciences, Pharmaceutical Sciences Research Center
rezaheidari@hotmail.com
10.30476/tips.2020.85962.1044
Multiple sclerosis (MS) is a neurodegenerative disease. Although multiple factors are involved in the pathogenesis of MS, there are several lines of evidence that oxidative stress and mitochondrial dysfunction are involved in neuronal demyelination and deterioration of MS symptoms. Hence, compounds that could modulate mitochondrial function and decrease mitochondria-mediated ROS formation might be able to decrease MS symptoms. Methylene blue (MB) is a compound widely used in the treatment of central nervous system disease (e.g., Alzheimer's disease). It has been found that MB could robustly suppress mitochondria-mediated ROS formation at low concentrations. The current study was designed to evaluate the effect of MB on neuronal demyelination, mitochondrial function, and ROS formation in an animal model of MS. C57BL/6 male mice received cuprizone (0.1% w: w in chow diet for 42 consecutive days). MB (0.5 and 1 mg/kg, oral) was simultaneously administered. Significant demyelination was detected in CPZ-treated animals, which confirm the induction of MS in the mice model. Decreased animals’ locomotor activity, including significant suppression of open field movement, stride length, and decreased time on the rotarod, was evident in CPZ-treated mice. Mitochondrial indices, including significantly elevated lipid peroxidation, mitochondrial depolarization, significant mitochondrial permeabilization, and decreased ATP levels, were also detected in the CPZ group. It was found that MB administration significantly improved animals’ locomotor activity and mitochondrial indices in the current animal model of MS. The effects of MB on mitochondria and mitochondria-mediated ROS formation might play a fundamental role in the protective effects of this compound.
ATP,Mitochondrial impairment,Neurodegeneration,Neurotoxicity,Oxidative stress
https://tips.sums.ac.ir/article_46502.html
https://tips.sums.ac.ir/article_46502_077bd81cb70ccc829739ed9e4c82e4b4.pdf
Shiraz University of Medical Sciences
Trends in Pharmaceutical Sciences
2423-3722
2423-5652
6
1
2020
03
01
The protective effects of Olive leaf extract on Type 2 diabetes, the expression of liver superoxide dismutase and total antioxidant capacity of plasma in rats
43
52
EN
Seyedeh mahsa
Hosseini nezhad motlagh
Department of Biochemistry,Shiraz Branch, Islamic Azad University, Shiraz, Iran
mahsahoseini194@gmail.com
mahmood
vessal
1 Department of Biochemistry, Shiraz Branch, Islamic Azad University, Shiraz, Iran
mahmoodv@yahoo.com
Rita
Arabsolghar
0000-0001-9725-8005
Department of Laboratory Sciences, School of Paramedical Sciences
Diagnostic Laboratory Sciences and Technology Research Center
Shiraz University of Medical Sciences
arabsolghar@sums.ac.ir
10.30476/tips.2020.82251.1038
Olive leaf has also medicinal benefits in type 2 diabetes. The aim of this cross-sectional study was to evaluate the effects of olive leaf extract on prevention of type 2 diabetes induced by Streptozotocin and nicotinamide, assessment of the expression of liver superoxide dismutase enzyme gene and total antioxidant capacity of plasma in rats. In this study 28 healthy, mature, Sprague-Dawely male rats with the initial weight of 250 ± 50 g were divided into 4 equal groups (group1: Healthy control; group2: Healthy Trial; group3: Diabetic control; group4: Diabetic Trial). Fasting blood glucose in all rats was measured every week with glucose oxidase method. At the end of our study, after sacrificing mice, all experiments were measured. Fasting blood glucose was not significant difference in the group 4(439 ± 47mg/dl) and group 3 (445 ± 33 mg/dl) but with group1(85 ± 11 mg/dl) significant difference was observed. There was no significant difference between total antioxidant activity and nitric oxide metabolites in groups but expression of superoxide dismutase gene was significantly increased in group2 and group3 (p <0.05). Histopathological results of liver in group 4 showed macrophages accumulation and mild inflammation and apoptosis in comparison with other groups. The extract of olive leaf with a dosage of 100 mg/kg did not reduce blood glucose in diabetic rats. Therefore, traditional methods used to treat diabetes type 1 and 2 do not only prevent but also diminish the ability to reduce blood sugar and can also cause damage to hepatocytes and other complications.
Olive leaf extract,Protective effects,Type2 diabetes,superoxide dismutase,total antioxidant capacity
https://tips.sums.ac.ir/article_46499.html
https://tips.sums.ac.ir/article_46499_e359107f05350cb0b7a0036342443242.pdf
Shiraz University of Medical Sciences
Trends in Pharmaceutical Sciences
2423-3722
2423-5652
6
1
2020
03
01
Erysimum cheiri: The potential uterotonic medicinal herb
53
56
EN
Ghazaleh
Mosleh
0000-0001-5664-4823
moslehgh@sums.ac.ir
Sasan
Zaeri
Department of Pharmacology, Faculty of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran
s.zaeri@bpums.ac.ir
Parmis
Badr
0000-0001-9136-6785
Phytopharmaceutical and Traditional Medicine Incubator, Shiraz University of Medical Sciences, Shiraz, Iran
badrp@sums.ac.ir
Abdolali
Mohagheghzadeh
0000-0002-4873-1449
Department of Traditional Pharmacy, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
mohaghegh@sums.ac.ir
10.30476/tips.2020.85358.1039
Wallflower (Erysimum cheiri (L.) Crantz) belonging to the family Brassicaceae has been a well-known medicinal herb in Persian medicine. Several cardiotonic steroids have isolated from different parts of this plant. The intravaginal dosage forms of wallflower have been frequently used for uterotonic purposes in traditional medicine. Accordingly, the present study explores the most frequent indications of wallflower through the history, and suggests a pharmacologcal hypothesis about the intravaginal delivery of this cardiotonic steroide cintaining herb. In this regard, study was done by searching via electronic databases and search engines including Sciencdirect and Scopus, Medline/Pubmed, and Google Scholar. Information on traditional indications of the herb was extracted from the major traditional medicine manuscripts. As the result, the historical survey and the pharmacological evidences have supported the hypothesis that the inhibitory effects of wallflower cardiotonic steroids on the Na+ K+ATPase pumps of the myocytes could affect the local vasospasm resulting the hypoxia, ischemia and contraction of the uterine tissue. It is suggested that more experimental studies be directed on the efficacy and safety of cardiotonic steroids of wallflower to induce uterine contractility.
Wallflower,Erysimum cheiri, Cardiotonic steroid,Uterotonic
https://tips.sums.ac.ir/article_46500.html
https://tips.sums.ac.ir/article_46500_cb3acbaf944ee6fee97b624d3f266ec8.pdf
Shiraz University of Medical Sciences
Trends in Pharmaceutical Sciences
2423-3722
2423-5652
6
1
2020
03
01
Fixed dosed combinations in the treatment of hypertension
57
64
EN
Gabriel
Hancu
0000-0003-2564-9271
University of Medicine, Pharmacy, Science and Technology &amp;amp;ldquo;George Emil Palade&amp;amp;rdquo; of T&amp;amp;acirc;rgu Mureș
gabriel.hancu@umfst.ro
Gabriel
Popescu
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Medicine, Pharmacy, Science and Technology “George Emil Palade” of Târgu Mureș, Târgu Mureș, Romania
popescu_gabriel_cosmin91@yahoo.com
Ștefana
Stăcescu
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Medicine, Pharmacy, Science and Technology “George Emil Palade” of Târgu Mureș, Târgu Mureș, Romania
stacescu.stefana@gmail.com
Eniko
Barabas-Hajdu
Department of Cell Biology and Microbiology, Faculty of Pharmacy, University of Medicine, Pharmacy, Science and Technology “George Emil Palade” of Târgu Mureș, Târgu Mureș, Romania
eniko.barabas@gmail.com
10.30476/tips.2020.85483.1040
Currently cardiovascular disease is the leading cause of mortality worldwide, resulting in approximately one third of all deaths globally. In order to address the role that hypertension plays in the morbidity and mortality of cardiovascular diseases, there is an urgent need for a paradigm shift in global hypertension management and treatment.<br /> Obtaining target pressure levels using monotherapy can be a difficult task especially in the case of patients with other associated diseases; consequently modern therapeutic guides recommend combinations of two ore more antihypertensives. Fixed dose combinations associate two or more pharmaceutical substances in a single pharmaceutical formulation; each drug typically working at a separate site, blocking different effector pathways.<br /> Compounds that struggle to be efficient in the monotherapy of patients with hypertension often become more effective if combined with another drug; associating drugs with different but complementary mechanism of action often leads to increased therapeutic efficacy.<br /> The current review presents the advantages of fixed dose combination and summarizes formulations of common dual, triple combinations used in therapy.
fixed-dose combinations,hypertension treatment,antihypertensives
https://tips.sums.ac.ir/article_46501.html
https://tips.sums.ac.ir/article_46501_f926a45a5009532a6f7418ba491641b2.pdf